Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Bavarian Nordic

181.55 DKK

+2.20 %

Less than 1K followers

BAVA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.20 %
-6.03 %
-4.87 %
-3.61 %
-22.41 %
+9.53 %
-7.16 %
-14.36 %
+27.28 %

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Read more
Market cap
14.39B DKK
Turnover
43.37M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.4.
2026

General meeting '26

13.5.
2026

Interim report Q1'26

21.8.
2026

Interim report Q2'26

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press releaseyesterday

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
Regulatory press releaseyesterday

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic
Regulatory press releaseyesterday

Bavarian Nordic Publishes Annual Report 2025

Bavarian Nordic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release3/11/2026, 7:30 AM

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

Bavarian Nordic
Regulatory press release3/2/2026, 6:42 AM

Paul Chaplin Steps Down as CEO of Bavarian Nordic

Bavarian Nordic
Press release2/18/2026, 7:00 AM

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

Bavarian Nordic
Regulatory press release2/12/2026, 6:43 AM

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Bavarian Nordic
Regulatory press release2/9/2026, 8:20 AM

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic
Regulatory press release2/2/2026, 7:54 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release1/26/2026, 7:20 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Press release1/23/2026, 7:00 AM

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

Bavarian Nordic
Regulatory press release1/19/2026, 7:35 AM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release1/12/2026, 12:17 PM

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic
Regulatory press release1/7/2026, 7:08 AM

Bavarian Nordic Launches Planned Share Buy-Back Program

Bavarian Nordic
Regulatory press release12/18/2025, 7:41 PM

Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees

Bavarian Nordic
Press release12/17/2025, 7:30 AM

Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic

Bavarian Nordic
Regulatory press release12/2/2025, 7:01 AM

Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million

Bavarian Nordic
Press release11/26/2025, 8:00 PM

Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen

Bavarian Nordic
Regulatory press release11/14/2025, 6:37 AM

Bavarian Nordic Announces Interim Results for the First Nine Months of 2025

Bavarian Nordic
Regulatory press release11/13/2025, 7:45 PM

Bavarian Nordic Announces Changes to the Board of Directors

Bavarian Nordic
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.